Agreement Between Innovative Medicines Initiative and Global Alzheimer’s Platform Will Accelerate Alzheimer’s Drug Development

Agreement Between Innovative Medicines Initiative and Global Alzheimer’s Platform Will Accelerate Alzheimer’s Drug Development
shutterstock_74106817The Innovative Medicines Initiative (IMI) together with the Global Alzheimer's Platform (GAP) recently announced the signing of a Memorandum of Understanding (MOU) agreement based on the common goal of accelerating the search for an Alzheimer’s disease therapy through the creation of a global, standing, trial-ready platform for Alzheimer's drug development. The announcement was made at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in Nice, France. “Alzheimer's disease is a global challenge that requires a global solution, and it is in this spirit that the IMI and GAP will collaborate and align their research. The Memorandum of Understanding is the evidence for our genuine interest in working together to create an international clinical trials platform,” said the IMI Acting Executive Director Dr. Irene Norstedt in a news release. “Everyone working on Alzheimer's disease needs to pull together if we want to deliver results that will help us to end the suffering caused by this terrible disease.” The aims of this global collaboration between the European IMI and the American GAP are to recruit patients for clinical trial studies, to generate
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *